RESEARCH ATLAS
← Compound index
COMPOUND RECORD / BRONCHOGEN

BronchogenБронхоген

Source linked

What the studies found

Comparison in people · 2014

Prospects of tetrapeptide application in treatment of chronic bronchitis: molecular mechanisms

Vital capacity, mean ± reported dispersion
3,650.5 ± 295.4 → 4,130.4 ± 121.1 mLControl: 3,735.6 ± 274.4 → 3,805.3 ± 276.7 mLBaseline → day 30
Expiratory forced vital capacity
2,740.7 ± 120.3 → 3,800.7 ± 116.1 mLControl: 2,850.0 ± 135.3 → 3,210.9 ± 136.6 mLBaseline → day 30
Total lung capacity
4,812.4 ± 254.10 → 5,300.5 ± 171.8 mLControl: 4,854.3 ± 246.8 → 5,120.2 ± 156.3 mL

In a 30-day comparison, vital capacity rose from 3,650.5 to 4,130.4 mL with oral Bronchogen plus standard care, versus 3,735.6 to 3,805.3 mL with standard care. Expiratory forced vital capacity rose from 2,740.7 to 3,800.7 mL versus 2,850.0 to 3,210.9 mL.

More reported outcomes
Subjective improvement
86% in the active groupGeneral wellbeing/symptoms; no corresponding control proportion supplied
Study notes · methods, sources and limitations

Participants or model 78 patients aged 34–65 with chronic bronchitis and an asthmatic component in remission; adjunctive Bronchogen 58, standard-care controls 20. Stratified randomization reported.

Design 78 patients aged 34–65 with chronic bronchitis and an asthmatic component in remission; adjunctive Bronchogen 58, standard-care controls 20. Stratified randomization reported.

Important limitations

  • No placebo or blinding described. The table measures forced vital capacity, not FEV1. Its significance footnote does not clearly resolve every within- versus between-group comparison. Oral capsule findings cannot be transferred to injectable or differently formulated products.

Molecular Medicine. 2014;(6):14–20 · Journal publication

Original source or citation ↗

Study results and tables ↗

Animal research · 2015

Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology

Bronchial and immune findings
Remodeling and inflammatory changes improved; secretory IgA increased

After one month of Bronchogen, rats showed less bronchial remodeling and neutrophilic inflammation, recovery of ciliated cells and increased secretory IgA. Numerical differences are not given in the abstract.

Study notes · methods, sources and limitations

Participants or model Rats exposed intermittently to nitrogen dioxide for 60 days to model obstructive lung disease.

Design Rats exposed intermittently to nitrogen dioxide for 60 days to model obstructive lung disease.

Model and treatment
60-day NO₂ exposure; 1-month Bronchogen course

Important limitations

  • A chemically induced rat model; related respiratory experiments may share the same research program. It does not establish prevention of human occupational lung injury.

Bulletin of experimental biology and medicine 2015 · Journal publication

Original source or citation ↗

Study results and tables ↗

Lab research · 2011

Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.

Findings for this preparation

Bronchogen (AEDL) preferentially interacted with CTG-containing DNA sequences in fluorescence assays. The cell-uptake experiment described in the abstract concerned other peptides.

Study notes · methods, sources and limitations

Participants or model HeLa cells and nucleic-acid fluorescence assays

Important limitations

  • Cell penetration and fluorescence-based binding do not establish hormonal, anti-aging or other clinical effects. Full methods, reporting completeness and independent replication remain to be appraised.

Biochemistry. Biokhimiia · PMID 22117547 · Original journal report

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Bronchogen

Names in this research collection

AEDL

A synthetic four-amino-acid peptide, AEDL, investigated in bronchial cells and respiratory disease. The library includes a 78-patient comparison using oral Bronchogen capsules alongside standard care.

Identity / background source ↗

Research background

AEDL tetrapeptide studied in bronchial cells, rat lung-injury models and a 78-patient oral-capsule comparison. The clinical report includes lung-volume measurements over 30 days.

More study findings

Lab research · 2012

Peptides tissue-specifically stimulate cell differentiation during their aging

Study of multiple preparations

Differentiation markers
CXCL12/Hoxa3 or CXCL12/WEGC1 expression increased in the corresponding cultures

Pancragen increased differentiation-marker expression in pancreatic cells, Bronchogen in bronchial cells, and Vesugen in prostatic fibroblasts. Responses were more pronounced in aged cultures.

Study notes · methods, sources and limitations

Participants or model Human embryonic pancreatic and bronchial cell cultures, plus human prostatic fibroblasts, compared at different passage ages.

Design Human embryonic pancreatic and bronchial cell cultures, plus human prostatic fibroblasts, compared at different passage ages.

Preparation assignments
Pancragen KEDW → pancreas; Bronchogen AEDL → bronchial cells; Vesugen KED → prostatic fibroblasts

Important limitations

  • Different peptides were tested in different cell types; this is not a combination trial or evidence of organ recovery in patients. No numerical effect sizes are supplied.

Bulletin of experimental biology and medicine 2012 · Journal publication

Original source or citation ↗

Study results and tables ↗

Research updates ↗

Compound class
Short peptide research
Research collection
Peptide bioregulation · editorial grouping
Research institutions
No institutional affiliation recorded
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

58 adjunctive-treatment patients and 20 standard-care controls; stratified randomization reported

Study methods

Original 2014 PDF clinical table checked; no placebo or blinding described

Independent replication

New citations are not automatically independent replication; shared programs and translated reports require cohort checks

Source access

Primary-publication records linked; full-text versus abstract review shown per source

Safety evidence

Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The 2014 oral-capsule comparison reports three lung-function outcomes. Group allocation and the significance footnote remain unclear. Independent replication and results for injectable AEDL remain separate evidence gaps.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗
PEPTIDE RESEARCH / OCT 2026

Related preparations and evidence

Evidence belongs to the preparation actually studied. A tissue extract and a synthetic peptide can belong to the same research tradition without having equivalent effects or safety.

Bronchial mucosa: the molecular link

Bronchial-mucosa polypeptide complex → Chonluten / EDG; Bronchogen / AEDL

The 2020 UHPLC–MS report identifies EDG and AEDL in bronchial-mucosa complex.

Clinical evidence and limitations

A Chonluten institute product report is now linked in the evidence map; its formulation is not independently characterized. The original 2014 Bronchogen report includes 58 adjunctive oral-capsule patients and 20 standard-care controls, with clinical lung-volume measurements.

Recover sequence-specific original experiments and clinical protocols; effects on respiratory disease and hazardous-exposure protection remain uncertain.

Related preparations

Chonluten ↗

Some references concern related extracts, reviews or molecular identification rather than direct studies of this compound.

Identification of short peptides in the composition of polypeptide complexes isolated from animal organs ↗Mechanism of Biological Activity of Short Peptides: Cell Penetration and Epigenetic Regulation of Gene Expression ↗

Explore the full bioregulator collection ↗

View this preparation in the Khavinson evidence map ↗

PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2009 · US7625870B2 · Bronchogen: AEDL respiratory peptideMolecule · Less interstitial fibrosis, atelectatic change and cellular infiltration described

Narrative findings; numerical extraction incomplete

The patent reports lower lung-injury changes and stimulation of explant growth, with selected blood-count changes during longer exposure.

Lung-injury findings
Less interstitial fibrosis, atelectatic change and cellular infiltration describedExperimental animal comparison; no transcribed clinical lung-function effect
Organotypic lung growth
Explant growth significantly stimulated over the stated 1–10 ng/mL rangeLaboratory tissue model; not human airway regeneration
All reported results, comparisons and limitations →

Molecule. Claim 1 explicitly identifies the tetrapeptide Ala-Glu-Asp-Leu, with respiratory-function composition and method claims.

This is AEDL, not the EDG tripeptide Chonluten. A respiratory label or a secondary review citation cannot resolve that sequence difference.

Publication
US7625870B2 ↗ · 2009-12-01
Earliest priority / filing
2004-06-22 / 2004-12-07
Original applicant / assignee
Access Bioscience CJSC
Indexed status
Expired - Fee Related · checked 2026-11-06
Patent family
34960198 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Peptide substance restoring respiratory organs function

Inventors: Vladimir Khatskelevich Khavinson; Galina Anatolievna Ryzhak; Evgeny Iosifovich Grigoriev; Irina Yurievna Ryadnova.

US7625870B2 · EP1758922B8 · ATE386046T1 · DE602004011842T2 · ES2302068T3 · RU2255757C1 · WO2006001729A1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Linked sources

Explore the research map and unresolved leads ↗

2009 · Bronchogen: AEDL respiratory peptide — US7625870B2Lung-injury findings: Less interstitial fibrosis, atelectatic change and cellular infiltration described
2009Patent / reported experimentsFull text available

Bronchogen: AEDL respiratory peptide — US7625870B2

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Vladimir Khatskelevich Khavinson, Galina Anatolievna Ryzhak, Evgeny Iosifovich Grigoriev, Irina Yurievna Ryadnova · US7625870B2 · patent family 34960198

The patent reports lower lung-injury changes and stimulation of explant growth, with selected blood-count changes during longer exposure.

Results and tables

Reported patent results

Narrative findings; numerical extraction incomplete

The patent reports lower lung-injury changes and stimulation of explant growth, with selected blood-count changes during longer exposure.

Bronchogen/AEDL preclinical lung-injury, organotypic culture and longer-term animal observations; no human respiratory trial established here.

Results · Experimental lung-injury and culture examples, Table 7 and longer-term blood observations.
MeasureResultComparison, timing and statistics
Lung-injury findingsLess interstitial fibrosis, atelectatic change and cellular infiltration describedExperimental animal comparison; no transcribed clinical lung-function effect
Organotypic lung growthExplant growth significantly stimulated over the stated 1–10 ng/mL rangeLaboratory tissue model; not human airway regeneration
Longer-term blood countsLeukocyte increase reported at six months; most other morphology/chemistry indices not significantly changedAn observed biological change, not proof of universal absence of adverse effects

These results concern AEDL, not EDG Chonluten. Animal pathology and culture growth cannot establish clinical respiratory efficacy or long-term human safety.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Bronchogen/AEDL preclinical lung-injury, organotypic culture and longer-term animal observations; no human respiratory trial established here.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • This is AEDL, not the EDG tripeptide Chonluten. A respiratory label or a secondary review citation cannot resolve that sequence difference.
  • These results concern AEDL, not EDG Chonluten. Animal pathology and culture growth cannot establish clinical respiratory efficacy or long-term human safety.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗
2014 · Prospects of tetrapeptide application in treatment of chronic bronchitis: molecular mechanismsVital capacity, mean ± reported dispersion: 3,650.5 ± 295.4 → 4,130.4 ± 121.1 mL
2014Human comparative studyFull text available

Prospects of tetrapeptide application in treatment of chronic bronchitis: molecular mechanisms

Oral Bronchogen capsule preparation described as AEDL · Journal publication

V. Kh. Khavinson, G. A. Ryzhak, N. S. Linkova, V. V. Ashapkin, A. O. Drobintseva, V. S. Basharina, B. F. Vanyushin · Molecular Medicine. 2014;(6):14–20

In a 30-day comparison, vital capacity rose from 3,650.5 to 4,130.4 mL with oral Bronchogen plus standard care, versus 3,735.6 to 3,805.3 mL with standard care. Expiratory forced vital capacity rose from 2,740.7 to 3,800.7 mL versus 2,850.0 to 3,210.9 mL.

Results and tables

Reported findings and study design

In a 30-day comparison, vital capacity rose from 3,650.5 to 4,130.4 mL with oral Bronchogen plus standard care, versus 3,735.6 to 3,805.3 mL with standard care. Expiratory forced vital capacity rose from 2,740.7 to 3,800.7 mL versus 2,850.0 to 3,210.9 mL.

78 patients aged 34–65 with chronic bronchitis and an asthmatic component in remission; adjunctive Bronchogen 58, standard-care controls 20. Stratified randomization reported.

Dose, route and schedule

Two capsules containing 0.1 mg active substance each, twice daily with meals for 30 days (0.4 mg/day), added to standard treatment. Reported study method, not a personal-use recommendation.

Protocol source ↗ · Original PDF p.17 clinical methods

Results · Original PDF pp.17–19; clinical methods and Table 3 visually checked
MeasureResultComparison, timing and statistics
Vital capacity, mean ± reported dispersion3,650.5 ± 295.4 → 4,130.4 ± 121.1 mLControl: 3,735.6 ± 274.4 → 3,805.3 ± 276.7 mL · Baseline → day 30
Expiratory forced vital capacity2,740.7 ± 120.3 → 3,800.7 ± 116.1 mLControl: 2,850.0 ± 135.3 → 3,210.9 ± 136.6 mL · Baseline → day 30
Total lung capacity4,812.4 ± 254.10 → 5,300.5 ± 171.8 mLControl: 4,854.3 ± 246.8 → 5,120.2 ± 156.3 mL
Subjective improvement86% in the active groupGeneral wellbeing/symptoms; no corresponding control proportion supplied
Table 3 · Respiratory measurements (mL)
Table 3 · Respiratory measurements (mL)
MeasureControl baselineBronchogen baselineControl afterBronchogen after
Vital capacity3735.6 ± 274.43650.5 ± 295.43805.3 ± 276.74130.4 ± 121.1*
Total lung capacity4854.3 ± 246.84812.4 ± 254.105120.2 ± 156.35300.5 ± 171.8*
Expiratory forced vital capacity2850.0 ± 135.32740.7 ± 120.33210.9 ± 136.6*3800.7 ± 116.1*

Values transcribed from the original table. * marks p<0.05 in the source, but the clinical comparison reference is not clearly specified. Both groups improved on forced vital capacity; this is not an FEV1 table.

No placebo or blinding described. The table measures forced vital capacity, not FEV1. Its significance footnote does not clearly resolve every within- versus between-group comparison. Oral capsule findings cannot be transferred to injectable or differently formulated products.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
78 patients aged 34–65 with chronic bronchitis and an asthmatic component in remission; adjunctive Bronchogen 58, standard-care controls 20. Stratified randomization reported.
Source reviewed
Original publisher PDF methods and clinical table checked; table visually verified.
Study limitations
  • No placebo or blinding described. The table measures forced vital capacity, not FEV1. Its significance footnote does not clearly resolve every within- versus between-group comparison. Oral capsule findings cannot be transferred to injectable or differently formulated products.

Reviewed 2026-11-01.

Read the source ↗
2015 · Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung PathologyBronchial and immune findings: Remodeling and inflammatory changes improved; secretory IgA increased
2015Animal / experimentalEnglish abstract

Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology

Defined synthetic peptide · Journal publication

Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, Surkova EA, Platonova IS, Titova ON · Bulletin of experimental biology and medicine 2015

After one month of Bronchogen, rats showed less bronchial remodeling and neutrophilic inflammation, recovery of ciliated cells and increased secretory IgA. Numerical differences are not given in the abstract.

Results and tables

Reported findings and study design

After one month of Bronchogen, rats showed less bronchial remodeling and neutrophilic inflammation, recovery of ciliated cells and increased secretory IgA. Numerical differences are not given in the abstract.

Rats exposed intermittently to nitrogen dioxide for 60 days to model obstructive lung disease.

Results · Primary-publication indexed abstract
MeasureResultComparison, timing and statistics
Bronchial and immune findingsRemodeling and inflammatory changes improved; secretory IgA increased
Model and treatment60-day NO₂ exposure; 1-month Bronchogen course

A chemically induced rat model; related respiratory experiments may share the same research program. It does not establish prevention of human occupational lung injury.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
Rats exposed intermittently to nitrogen dioxide for 60 days to model obstructive lung disease.
Source reviewed
Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
  • A chemically induced rat model; related respiratory experiments may share the same research program. It does not establish prevention of human occupational lung injury.

Reviewed 2026-11-01.

Read the source ↗
2012 · Peptides tissue-specifically stimulate cell differentiation during their agingDifferentiation markers: CXCL12/Hoxa3 or CXCL12/WEGC1 expression increased in the corresponding cultures
2012In vitroEnglish abstract

Peptides tissue-specifically stimulate cell differentiation during their aging

Defined synthetic peptides · Journal publication

Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM · Bulletin of experimental biology and medicine 2012

Pancragen increased differentiation-marker expression in pancreatic cells, Bronchogen in bronchial cells, and Vesugen in prostatic fibroblasts. Responses were more pronounced in aged cultures.

Results and tables

Reported findings and study design

Pancragen increased differentiation-marker expression in pancreatic cells, Bronchogen in bronchial cells, and Vesugen in prostatic fibroblasts. Responses were more pronounced in aged cultures.

Human embryonic pancreatic and bronchial cell cultures, plus human prostatic fibroblasts, compared at different passage ages.

Results · Primary-publication indexed abstract
MeasureResultComparison, timing and statistics
Differentiation markersCXCL12/Hoxa3 or CXCL12/WEGC1 expression increased in the corresponding cultures
Preparation assignmentsPancragen KEDW → pancreas; Bronchogen AEDL → bronchial cells; Vesugen KED → prostatic fibroblasts

Different peptides were tested in different cell types; this is not a combination trial or evidence of organ recovery in patients. No numerical effect sizes are supplied.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
Human embryonic pancreatic and bronchial cell cultures, plus human prostatic fibroblasts, compared at different passage ages.
Source reviewed
Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
  • Different peptides were tested in different cell types; this is not a combination trial or evidence of organ recovery in patients. No numerical effect sizes are supplied.

Reviewed 2026-11-01.

Read the source ↗
2011 · Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.
2011In vitroEnglish abstract

Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.

· Original journal report

Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF · Biochemistry. Biokhimiia · PMID 22117547

The paper identifies Testagen as Lys–Glu–Asp–Gly (KEDG). Labeled short peptides entered cells and nuclei; binding patterns differed between DNA sequences.

Population / setting
HeLa cells and nucleic-acid fluorescence assays
Source reviewed
Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
  • Cell penetration and fluorescence-based binding do not establish hormonal, anti-aging or other clinical effects.
  • Full methods, reporting completeness and independent replication remain to be appraised.

Reviewed 2026-10-05.

Read the source ↗
2006 · The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats
2006In vitroEnglish abstract

The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats

Synthetic peptide / defined-sequence research · Journal publication

Zakutskiĭ AN, Chalisova NI, Ryzhak GA, Aniskina AI, Filippov SV, Zeziulin PN · Advances in gerontology = Uspekhi gerontologii 19():93-96. PMID 17152728

Reports tissue-specific growth responses to the corresponding synthetic peptides in organotypic cultures.

Population / setting
Heart, lung, prostate and pancreatic explants from young and old rats
Source reviewed
Europe PMC indexed citation and abstract checked. Full original paper not reviewed.
Study limitations
  • Ex vivo animal tissue, not a human clinical study or evidence that an extract and peptide are interchangeable.
  • Full methods, adverse-event reporting and independent replication remain to be appraised.

Reviewed 2026-09-30.

Read the source ↗
2020 · Identification of short peptides in the composition of polypeptide complexes isolated from animal organs
2020Analytical / composition studyRussian source · see review scope

Identification of short peptides in the composition of polypeptide complexes isolated from animal organs

I. K. Zhurkovich, N. G. Kovrov, G. A. Ryzhak, E. S. Mironova, V. Kh. Khavinson · Uspekhi Sovremennoi Biologii 140(2):140–148

Reports KED in vessel complex, AED in cartilage, EDG and AEDL in bronchial mucosa, EDR in brain and KEDW in pancreas. This strengthens sequence-level links in the research program.

Population / setting
Animal-organ polypeptide complexes analyzed by UHPLC–MS
Source reviewed
Author-hosted Russian PDF: citation and indexed abstract checked; full analytical validation and product-batch equivalence not appraised.
Study limitations
  • Molecular detection does not prove identical pharmacology or clinical equivalence.
  • The paper’s discussion of clinical work is not an independent clinical trial.

Reviewed 2026-09-29.

Read the source ↗
2013 · Mechanism of Biological Activity of Short Peptides: Cell Penetration and Epigenetic Regulation of Gene Expression
2013ReviewFull text available

Mechanism of Biological Activity of Short Peptides: Cell Penetration and Epigenetic Regulation of Gene Expression

V. Kh. Khavinson, A. Yu. Solovyev, S. I. Tarnovskaya, N. S. Linkova · Biology Bulletin Reviews 3(6):451–455

Mechanistic review with a table of 15 short peptides on page 453. Tissue labels in the research map are the authors’ proposed targets, not established clinical indications.

Population / setting
Review of earlier research
Source reviewed
Author-hosted English PDF and its peptide table checked. Each cited experiment remains a separate appraisal task.
Study limitations
  • Source-linked does not mean a completed risk-of-bias review.
  • A review is not an independent clinical replication; proposed mechanisms do not establish efficacy or safety.

Reviewed 2026-09-27.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Pancragen research ↗

4 shared source records

Pinealon research ↗

3 shared source records

Vesugen research ↗

3 shared source records

Cardiogen research ↗

2 shared source records

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗